Reconstitution Guide

What reconstitution means

Most peptides sold for research arrive as a lyophilized (freeze-dried) powder in a sealed glass vial. Reconstitution is the step where a liquid diluent is added so the powder dissolves into a solution that can be measured. Peptides are shipped dry for a reason: a 2023 review in Pharmaceutics describes peptides as often unstable in water, which is why so many are made as dry powders for reconstitution even though a ready-made liquid would be more convenient.

As of October 2026, research-grade peptide vials are not approved by the FDA for human use, and this page is not a set of instructions. It summarizes what pharmacy standards and drug labels say, alongside what community guides describe. The distinction has legal weight. In warning letters dated August 24, 2026, FDA said that selling bacteriostatic water next to research peptides, or offering a "peptide calculator" and "peptide guide", was evidence the products were meant to be injected by people, whatever their "research use only" labels said.

Two pages sit under this one. The page on sterile technique for peptide preparation covers how contamination happens during handling. The page on peptide storage best practices goes into temperatures and timelines.

Diluents described in lab references

Bacteriostatic water is the diluent named most often. Hospira's FDA-approved label describes Bacteriostatic Water for Injection, USP as sterile water with 0.9% (9 mg/mL) benzyl alcohol added as a preservative, at a pH of about 5.7. The label calls it "for drug diluent use only" and says it must not be used in newborns, because benzyl alcohol has been linked to toxicity in neonates. It is indicated only for dissolving drugs "according to instructions of the manufacturer of the drug to be administered." The same label says reconstituted solutions shouldn't be stored unless the drug's manufacturer directs it. Research vials come with no manufacturer instructions of that kind, a gap that runs through everything below.

Preservative-free sterile water is the other diluent that comes up. Without a preservative, nothing slows bacterial growth after the first puncture. CDC's injection-safety guidance treats preservative-free single-dose vials as one-use containers and advises against saving leftovers, since they can become a source of infection.

Benzyl alcohol is not inert for every molecule. In a 2006 lab study of the protein drug G-CSF, 0.9% benzyl alcohol sped up aggregation at pH 7.0, with a much larger effect at 37 °C than at 25 °C, and caused no aggregation at pH 3.5. Researchers have reported the same kind of effect with interferon alfa-2a, where aggregation rose with benzyl alcohol concentration. These are large proteins rather than the short peptides in most research vials, so nobody knows how far the finding carries over. Some community guides mention dilute acetic acid for peptides that dissolve poorly near neutral pH. We couldn't trace that practice to a published stability study.

Approved peptide products show how product-specific this gets. Egrifta WR (tesamorelin), a prescription medicine, ships with its own 30 mL bottle of bacteriostatic water, and its label names that diluent and no other.

How concentration is worked out

Concentration is the peptide's mass divided by the volume of liquid. On paper the arithmetic is simple: 10 mg dissolved in 2 mL works out to 5 mg/mL, or 5,000 mcg per mL. Real labels are less tidy. The Egrifta WR label lists 11.6 mg of tesamorelin plus 1.3 mL of bacteriostatic water and states the result as 8 mg/mL, lower than simple division gives. The label doesn't explain the gap, which is a reminder that a labeled concentration is set by the manufacturer, not worked out by hand.

A research vial has no validated figure at all. The math rests on the mass printed on the vial, and independent testing (covered below) suggests that number is often wrong. Community guides usually go one step further and convert a concentration into syringe markings for a chosen amount. That conversion is the kind of tool FDA cited in its 2026 letters, and this page doesn't reproduce it.

Sterility once a vial is opened

Each needle puncture is a chance to carry microbes into the vial. CDC's guidance for clinicians says the preservative in multi-dose vials "does not have an effect on viruses nor does it provide complete protection against bacterial contamination." It warns against leaving a needle in a vial's rubber septum, because that gives microorganisms a direct route inside. CDC also advises preparing an injection as close as possible to the time it's given, citing sterility as well as the drug's physical and chemical stability.

USP General Chapter <797>, the US standard for sterile compounding, became official on November 1, 2023. CDC notes that the chapter's definition of compounding includes reconstituting a drug. As CDC summarizes the standard, an opened multi-dose vial should be dated and thrown out within 28 days unless the manufacturer gives a different date. The Egrifta WR label applies the same 28-day limit to its bottle of bacteriostatic water. A hand-mixed research vial isn't a manufactured multi-dose product, though. No one has tested how long one stays sterile, so the 28-day figure is borrowed rather than earned.

Storage before and after mixing

A 2023 review in Advanced Drug Delivery Reviews notes that most lyophilized peptides stay stable for several years at -20 °C when protected from light, while their shelf life in solution is "very limited and much shorter." The same review says peptides containing cysteine or methionine are prone to oxidation, as are those with tryptophan, and that freeze-thaw cycles and high pH speed it up.

Community guides nearly always describe refrigerating a vial after mixing, and the storage page covers the ranges they give. Labels for approved products show that the right answer depends on the formulation. Egrifta WR's label calls for room temperature (20-25 °C) after mixing, says not to refrigerate or freeze it, and sets a 7-day limit before the rest is discarded. A research vial has no label like that, so any storage window for it is an estimate.

What breaks peptides down

The 2023 Pharmaceutics review sorts degradation into two groups. Chemical pathways form or break covalent bonds; deamidation and oxidation are common examples. Physical pathways change how molecules interact without altering them chemically, for instance when they clump into aggregates or stick to the vial wall. That review names pH and buffer choice as the most practical ways to slow degradation in solution. The Advanced Drug Delivery Reviews paper adds that deamidation is slowest at about pH 3-6.

A 2017 review of peptide aggregation covers the factors that push peptides to clump. Concentration and pH matter, and so does physical stress such as agitation or contact with surfaces. That fits a detail in the Egrifta WR instructions, which say to swirl the vial and not shake it.

The bacteriostatic water label asks that reconstituted drugs be checked for clarity and for any precipitate or discoloration before use. A visual check can't detect chemical changes like deamidation, which take lab analysis to find, so a clear solution isn't proof that the peptide is intact.

Quality problems reconstitution can't fix

Everything above assumes the powder is what the label says. A preprint posted in April 2026 (not yet peer-reviewed) pooled 6,441 independent test results across 14 gray-market peptides. Depending on which quality standard was applied, 41.6% to 71.1% of samples failed basic criteria. Only 243 samples had been tested for endotoxin (a bacterial toxin), and 15% of those had measurable levels. The authors call third-party testing an improvement in transparency, but one that captures only a small part of the safety picture.

A preservative in the diluent is meant to limit bacteria introduced during use. It can't correct a vial that holds the wrong amount of peptide or arrived already contaminated.

What we still don't know

We found no published stability studies for most research peptides dissolved in bacteriostatic water and kept refrigerated. The multi-week shelf-life figures that circulate in community guides appear to come from vendors and forums, not from measured data.

It's also unclear whether the benzyl alcohol findings in large proteins apply to short peptides, or whether the 28-day multi-dose rule means much for a vial mixed by hand. Until someone tests these questions directly, the honest summary is that reconstituted research vials have no established shelf life.